{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Anti-proliferative", "EGFR inhibitors", "apoptosis", "docking studies", "pyrido[2,3-d]pyrimidin-4(3H)-one"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35821615", "DateCompleted": {"Year": "2022", "Month": "07", "Day": "14"}, "DateRevised": {"Year": "2022", "Month": "07", "Day": "20"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1080/14756366.2022.2062752"], "Journal": {"ISSN": "1475-6374", "JournalIssue": {"Volume": "37", "Issue": "1", "PubDate": {"Year": "2022", "Month": "Dec"}}, "Title": "Journal of enzyme inhibition and medicinal chemistry", "ISOAbbreviation": "J Enzyme Inhib Med Chem"}, "ArticleTitle": "Design, synthesis, and anti-cancer evaluation of new pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers.", "Pagination": {"StartPage": "1053", "EndPage": "1076", "MedlinePgn": "1053-1076"}, "Abstract": {"AbstractText": ["A new series of pyrido[2,3-d]pyrimidin-4(3H)-one derivatives having the essential pharmacophoric features of EGFR inhibitors has been designed and synthesised. Cell viability screening was performed for these compounds against A-549, PC-3, HCT-116, and MCF-7 cell lines at a dose of 100\u2009\u03bcM. The highest active derivatives (<b>8a, 8\u2009b, 8d, 9a,</b> and <b>12b</b>) were selected for IC<sub>50</sub> screening. Compounds <b>8a, 8\u2009b,</b> and <b>9a</b> showed the highest cytotoxic activities and were further investigated for wild EGFR<sup>WT</sup> and mutant EGFR<sup>T790M</sup> inhibitory activities. Compound <b>8a</b> showed the highest inhibitory activities against EGFR<sup>WT</sup> and EGFR<sup>T790M</sup> with IC<sub>50</sub> values of 0.099 and 0.123\u2009\u00b5M, respectively. In addition, it arrested the cell cycle at pre-G1 phase and induced a significant apoptotic effect in PC-3 cells. Furthermore, compound <b>8a</b> induced a 5.3-fold increase in the level of caspase-3 in PC-3 cells. Finally, docking studies were carried out to examine the binding mode of the synthesised compounds against both EGFR<sup>WT</sup> and EGFR<sup>T790M</sup>."]}, "AuthorList": [{"Identifier": ["0000-0002-7023-6364"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt."}], "LastName": "Elzahabi", "ForeName": "Heba S A", "Initials": "HSA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt."}], "LastName": "Nossier", "ForeName": "Eman S", "Initials": "ES"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt."}], "LastName": "Alasfoury", "ForeName": "Rania A", "Initials": "RA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy Department, National Research Centre, Dokki, Cairo, Egypt."}], "LastName": "El-Manawaty", "ForeName": "May", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt."}], "LastName": "Sayed", "ForeName": "Sara M", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Organic Chemistry, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt."}], "LastName": "Hagras", "ForeName": "Mohamed", "Initials": "M"}, {"Identifier": ["0000-0002-6955-2263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Enzyme Inhib Med Chem", "NlmUniqueID": "101150203", "ISSNLinking": "1475-6366"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Apoptosis"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["metabolism"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Lung Neoplasms"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": [], "DescriptorName": "Mutation"}, {"QualifierName": [], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}], "CoiStatement": "No potential conflict of interest was reported by the author(s)."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "WHO. Cancer . Available from: https://www.who.int/news-room/fact-sheets/detail/cancer. (last accessed 13 Jan 2022)."}, {"Citation": "Boyle P, Ferlay JJ.. Cancer incidence and mortality in Europe, 2004. Annals Oncol 2005;16:481\u20138.", "ArticleIdList": ["15718248"]}, {"Citation": "Gavalas NG, Karadimou A, Dimopoulos MA, et al. . Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. J Immunol Res 2010;2010:1\u201315.", "ArticleIdList": ["PMC3034919", "21318181"]}, {"Citation": "Li M, Huo X, Davuljigari CB, et al. . MicroRNAs and their role in environmental chemical carcinogenesis. Environ Geochem Health 2019;41:225\u201347.", "ArticleIdList": ["30171477"]}, {"Citation": "Chorawala M, Oza P, Shah GJ.. Mechanisms of anticancer drugs resistance: an overview. J Pharm Technol Drug Res 2012;4:1\u20139."}, {"Citation": "Lavogina D, Enkvist E, Uri A.. Bisubstrate inhibitors of protein kinases: from principle to practical applications. ChemMedChem 2010;5:23\u201334.", "ArticleIdList": ["19774589"]}, {"Citation": "Lukovi\u0107 E, Gonz\u00e1lez-Vera JA, Imperiali B.. Recognition-domain focused chemosensors: versatile and efficient reporters of protein kinase activity. J Am Soc 2008;130:12821\u20137.", "ArticleIdList": ["PMC2637182", "18759402"]}, {"Citation": "Braun T, Gautel MJ.. Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis. Nat Rev Mol cell Biol 2011;12:349\u201361.", "ArticleIdList": ["21602905"]}, {"Citation": "Meulenbeld HJ, Mathijssen RH, Verweij J, et al. . Danusertib, an aurora kinase inhibitor. Expert Opin Investig Drugs 2012;21:383\u201393.", "ArticleIdList": ["22242557"]}, {"Citation": "Abdellatif KR, Bakr RB.. Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment. Med Chem J 2021;30:31\u201349."}, {"Citation": "Ullrich A, Schlessinger J.. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203\u201312.", "ArticleIdList": ["2158859"]}, {"Citation": "Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS.. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997;8:1197\u2013206.", "ArticleIdList": ["9496384"]}, {"Citation": "Meierjohann S, Mueller T, Schartl M, Buehner MJZ.. A structural model of the extracellular domain of the oncogenic EGFR variant Xmrk. Zebrafish 2006;3:359\u201369.", "ArticleIdList": ["18377216"]}, {"Citation": "Ren S, Chen X, Kuang P, et al. . Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer 2012;118:5588\u201394.", "ArticleIdList": ["22569898"]}, {"Citation": "Normanno N, De Luca A, Bianco C, et al. . Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2\u201316.", "ArticleIdList": ["16377102"]}, {"Citation": "Godin-Heymann N, Ulkus L, Brannigan BW, et al. . The T790M \u201cgatekeeper\u201d mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 2008;7:874\u20139.", "ArticleIdList": ["18413800"]}, {"Citation": "Abdelsalam EA, Zaghary WA, Amin KM, et al. . Synthesis and in\u00a0vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors. Bioorg Chem 2019;89:102985.", "ArticleIdList": ["31121559"]}, {"Citation": "Ismail RS, Abou-Seri SM, Eldehna WM, et al. . Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells. Eur J Med Chem 2018;155:782\u201396.", "ArticleIdList": ["30047410"]}, {"Citation": "Gandin V, Ferrarese A, Dalla Via M, et al. . Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Sci Rep 2015;5:16750.", "ArticleIdList": ["PMC4645160", "26568452"]}, {"Citation": "Traxler P, Furet P.. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Therapeutics 1999;82:195\u2013206.", "ArticleIdList": ["10454197"]}, {"Citation": "Zhang J, Yang PL, Gray NS.. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28\u201339.", "ArticleIdList": ["19104514"]}, {"Citation": "Gaber AA, Bayoumi AH, El-Morsy AM, et al. . Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers. Bioorg Chem 2018;80:375\u201395.", "ArticleIdList": ["29986185"]}, {"Citation": "Sharma VK, Nandekar PP, Sangamwar A, et al. . Structure guided design and binding analysis of EGFR inhibiting analogues of erlotinib and AEE788 using ensemble docking, molecular dynamics and MM-GBSA. RSC Adv 2016;6:65725\u201335."}, {"Citation": "Mowafy S, Galanis A, Doctor ZM, et al. . Toward discovery of mutant EGFR inhibitors; design, synthesis and in\u00a0vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives. Biorg Med Chem 2016;24:3501\u201312.", "ArticleIdList": ["27288180"]}, {"Citation": "Zhao Z, Wu H, Wang L, et al. . Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol 2014;9:1230\u201341.", "ArticleIdList": ["PMC4068218", "24730530"]}, {"Citation": "Liu Y, Gray NS.. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358\u201364.", "ArticleIdList": ["16783341"]}, {"Citation": "Bonomi P. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Invest Drugs 2003;12:1395\u2013401.", "ArticleIdList": ["12882624"]}, {"Citation": "Pao W, Wang TY, Riely GJ, et al. . KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.", "ArticleIdList": ["PMC545207", "15696205"]}, {"Citation": "Pao W, Miller VA, Politi KA, et al. . Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLOS Med 2005;2:e73.", "ArticleIdList": ["PMC549606", "15737014"]}, {"Citation": "Kobayashi S, Boggon TJ, Dayaram T, et al. . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786\u201392.", "ArticleIdList": ["15728811"]}, {"Citation": "Kwak EL, Sordella R, Bell DW, et al. . Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102:7665\u201370.", "ArticleIdList": ["PMC1129023", "15897464"]}, {"Citation": "Engelman JA, Zejnullahu K, Gale C-M, et al. . PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924\u201332.", "ArticleIdList": ["18089823"]}, {"Citation": "Li D, Ambrogio L, Shimamura T, et al. . BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702\u201311.", "ArticleIdList": ["PMC2748240", "18408761"]}, {"Citation": "\u00a0Sohn SH, Sul HJ, Kim B, et al. RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancer. J Cancer. 2021;12:4616\u201325.", "ArticleIdList": ["PMC8210561", "34149925"]}, {"Citation": "Sequist LV, Besse B, Lynch TJ, et al. . Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non\u2013small-cell lung cancer. J Clin Oncol 2010;28:3076\u201383.", "ArticleIdList": ["20479403"]}, {"Citation": "Kim Y, Ko J, Cui Z, et al. . The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Therapeutics 2012;11:784\u201391.", "ArticleIdList": ["22228822"]}, {"Citation": "J\u00e4nne PA, Yang JC-H, Kim D-W, et al. . AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689\u201399.", "ArticleIdList": ["25923549"]}, {"Citation": "Carroll J.. Following lethal tox report, Boehringer scraps plans for high-speed development, kills $730M Hanmi deal; 2016. Available from: https://endpts.com/following-lethal-tox-report-boehringer-scraps-plans-for-high-speed-development-kills-730m-hanmi-deal/. (last accessed May 2019)."}, {"Citation": "P, Callery, G, Peter Cancer and cancer chemotherapy. In: David, AW and Thomas, LL, eds. Foye\u2019s principles of medical chemistry. Philadelphia: Lippincott, Williams and Wilkins; 2002."}, {"Citation": "Abdel-Mohsen HT, Ragab FA, Ramla MM, El Diwani HI.. Novel benzimidazole-pyrimidine conjugates as potent antitumor agents. Eur J Med Chem 2010;45:2336\u201344.", "ArticleIdList": ["20356655"]}, {"Citation": "Shao H, Shi S, Foley DW, et al. . Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents. Eur J Med Chem 2013;70:447\u201355.", "ArticleIdList": ["24185375"]}, {"Citation": "Fathalla O, Zeid I, Haiba M, et al. . Synthesis, antibacterial and anticancer evaluation of some pyrimidine derivatives. World J Chem 2009;4:127\u201332."}, {"Citation": "Yu L, Huang M, Xu T, et al. . A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties. Eur J Med Chem 2017;126:1107\u201317.", "ArticleIdList": ["28033579"]}, {"Citation": "Xu T, Peng T, Ren X, et al. . C5-substituted pyrido [2, 3-d] pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR T790M mutant. MedChemComm 2015;6:1693\u20137."}, {"Citation": "El-Naggar AM, Abou-El-Regal MM, El-Metwally SA, et al. . Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents. Mol Div 2017;21:967\u201383.", "ArticleIdList": ["28815411"]}, {"Citation": "Eldehna WM, Abo-Ashour MF, Nocentini A, et al. . Novel 4/3-((4-oxo-5-(2-oxoindolin-3-ylidene)thiazolidin-2-ylidene)amino) benzenesulfonamides: synthesis, carbonic anhydrase inhibitory activity, anticancer activity and molecular modelling studies. Eur J Med Chem 2017;139:250\u201362.", "ArticleIdList": ["28802125"]}, {"Citation": "El-Naggar AM, Eissa IH, Belal A, El-Sayed AA.. Design, eco-friendly synthesis, molecular modeling and anticancer evaluation of thiazol-5 (4\u2009H)-ones as potential tubulin polymerization inhibitors targeting the colchicine binding site. RSC Adv 2020;10:2791\u2013811.", "ArticleIdList": ["PMC9048505", "35496078"]}, {"Citation": "Eissa IH, El-Naggar AM, El-Hashash MA.. Design, synthesis, molecular modeling and biological evaluation of novel 1H-pyrazolo[3,4-b]pyridine derivatives as potential anticancer agents. Bioorg Chem 2016;67:43\u201356.", "ArticleIdList": ["27253830"]}, {"Citation": "Eissa IH, El-Naggar AM, Abd El-Sattar NE, Youssef AS.. Design and discovery of novel quinoxaline derivatives as dual DNA intercalators and topoisomerase II inhibitors. Anti-Cancer Agents Med Chem 2018;18:195\u2013209.", "ArticleIdList": ["28699490"]}, {"Citation": "Ibrahim M, Taghour M, Metwaly A, et al. . Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors. Eur J Med Chem 2018;155:117\u201334.", "ArticleIdList": ["29885574"]}, {"Citation": "Eissa IH, Metwaly AM, Belal A, et al. . Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors. Archiv der Pharmazie 2019;352:1900123.", "ArticleIdList": ["31463953"]}, {"Citation": "Mahdy HA, Ibrahim MK, Metwaly AM, et al. . Design, synthesis, molecular modeling, in\u00a0vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Bioorg Chem 2020;94:103422.", "ArticleIdList": ["31812261"]}, {"Citation": "El\u2010Helby AGA, Sakr H, Eissa IH, et al. . Benzoxazole/benzothiazole\u2010derived VEGFR\u20102 inhibitors: design, synthesis, molecular docking, and anticancer evaluations. Archiv der Pharmazie 2019;352:1900178.", "ArticleIdList": ["31596514"]}, {"Citation": "Elmetwally SA, Saied KF, Eissa IH, Elkaeed EB.. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Bioorg Chem 2019;88:102944.", "ArticleIdList": ["31051400"]}, {"Citation": "Nasser AA, Eissa IH, Oun MR, et al. . Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFRWT and EGFRT790M. Org Biomol Chem 2020;18:7608\u201334.", "ArticleIdList": ["32959865"]}, {"Citation": "Othman IM, Alamshany ZM, Tashkandi NY, et al. . New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: synthesis, anticancer, antimicrobial evaluation and computational studies. Bioorg Chem 2021;114:105078.", "ArticleIdList": ["34161878"]}, {"Citation": "Abd El-Meguid EA, Moustafa GO, Awad HM, et al. . Novel benzothiazole hybrids targeting EGFR: design, synthesis, biological evaluation and molecular docking studies. Anticancer Agents Med Chem 2021;1240:130595."}, {"Citation": "Khattab RR, Alshamari AK, Hassan AA, et al. . Click chemistry based synthesis, cytotoxic activity and molecular docking of novel triazole-thienopyrimidine hybrid glycosides targeting EGFR. J Enzyme Inhib Med Chem 2021;36:504\u201316.", "ArticleIdList": ["PMC8759726", "33504239"]}, {"Citation": "Elzahabi HS, Nossier ES, Khalifa NM, et al. . Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold. J Enzyme Inhib Med Chem 2018;33:546\u201357.", "ArticleIdList": ["PMC6009920", "29482389"]}, {"Citation": "Khalifa NM, Adel A-H, Abd-Elmoez SI, et al. . A convenient synthesis of some new fused pyridine and pyrimidine derivatives of antimicrobial profiles. Res Chem Intermed 2015;41:2295\u2013305."}, {"Citation": "Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55\u201363.", "ArticleIdList": ["6606682"]}, {"Citation": "Denizot F, Lang RJJoim.. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89:271\u20137.", "ArticleIdList": ["3486233"]}, {"Citation": "Thabrew MI, Hughes RD, McFarlane IGJJop.. Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J Pharm Pharmacol 2011;49:1132\u20135.", "ArticleIdList": ["9401951"]}, {"Citation": "Jia Y, Quinn CM, Gagnon AI, Talanian R.. Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. Anal Biochem 2006;356:273\u201381.", "ArticleIdList": ["16814737"]}, {"Citation": "Wang J, Lenardo MJ.. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci 2000;113:753\u20137.", "ArticleIdList": ["10671365"]}, {"Citation": "Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C.. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 1995;184:39\u201351.", "ArticleIdList": ["7622868"]}, {"Citation": "Earnshaw WC, Martins LM, Kaufmann SH.. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Ann Rev Biochem 1999;68:383\u2013424.", "ArticleIdList": ["10872455"]}, {"Citation": "Bortner CD, Cidlowski JA.. Apoptotic volume decrease and the incredible shrinking cell. Cell Death Different 2002;9:1307\u201310.", "ArticleIdList": ["12478467"]}, {"Citation": "Bae SS, Choi JH, Oh YS, et al. . Proteolytic cleavage of epidermal growth factor receptor by caspases. FEBS Lett 2001;491:16\u201320.", "ArticleIdList": ["11226410"]}, {"Citation": "He Y, Huang J, Chignell C.. Cleavage of epidermal growth factor receptor by caspase during apoptosis is independent of its internalization. Oncogene 2006;25:1521\u201331.", "ArticleIdList": ["16247443"]}, {"Citation": "Park JH, Liu Y, Lemmon MA, Radhakrishnan R.. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J 2012;448:417\u201323.", "ArticleIdList": ["PMC3507260", "23101586"]}, {"Citation": "Sogabe S, Kawakita Y, Igaki S, et al. . Structure-based approach for the discovery of pyrrolo[3,2-d]pyrimidine-based EGFR T790M/L858R mutant inhibitors. ACS Med Chem Lett 2013;4:201\u20135.", "ArticleIdList": ["PMC4027575", "24900643"]}, {"Citation": "Taylor EC, Cheng C.. Studies in purine chemistry. VI. A convenient one-step synthesis of hypoxanthine. J Am Chem Soc 1959;1:9\u201311."}, {"Citation": "Eldehna WM, Hassan GS, Al-Rashood ST, et al. . Synthesis and in\u00a0vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. J Enzyme Inhib Med Chem 2019;34:322\u201332.", "ArticleIdList": ["PMC6366416", "30722708"]}, {"Citation": "Al-Warhi T, Abo-Ashour MF, Almahli H, et al. . Novel [(N-alkyl-3-indolylmethylene)hydrazono]oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl-2: synthesis, biological evaluation and in silico studies. J Enzyme Inhib Med Chem 2020;35:1300\u20139.", "ArticleIdList": ["PMC7717600", "32522063"]}, {"Citation": "Lo KK-W, Lee TK-M, Lau JS-Y, et al. . Luminescent biological probes derived from ruthenium(II) estradiol polypyridine complexes. Inorg Chem 2008;47:200\u20138.", "ArticleIdList": ["18067284"]}, {"Citation": "Sabt A, Abdelhafez OM, El-Haggar RS, et al. . Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in\u00a0vitro biological evaluation, and QSAR studies. J Enzyme Inhib Med Chem 2018;33:1095\u2013107.", "ArticleIdList": ["PMC6022226", "29944015"]}, {"Citation": "Al-Sanea MM, Al-Ansary GH, Elsayed ZM, et al. . Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells. J Enzyme Inhib Med Chem 2021;36:987\u201399.", "ArticleIdList": ["PMC8128204", "33985397"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "7", "Day": "13", "Hour": "0", "Minute": "48"}, {"Year": "2022", "Month": "7", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "12"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35821615", "PMC9291687", "10.1080/14756366.2022.2062752"]}}], "PubmedBookArticle": []}